Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eleanor Malone

London, UK
Eleanor has been editor of Scrip Intelligence since 2014. She has more than 15 years’ experience writing specialist news and analysis for and about the biopharma industry. She holds an MA in modern languages from the University of Edinburgh. Based in London, she appears regularly on TV and radio and conference panels to discuss matters related to the industry.
Advertisement
Set Alert for Articles By Eleanor Malone

Latest From Eleanor Malone

Ten Strategies For Success In Antibody-Drug Conjugate Development

The future looks rosy after a slow start for antibody-drug conjugates. But what are the best tactics to capture a slice of the growing opportunity?

Research and Development Strategies Platform Technologies

Versantis Gets Cash For Toxin 'Undelivery' Product

Emerging Company Profile: CHF16m for Swiss firm that engineers liposomes to capture toxins and protect the organs of patients with acute liver failure.

 

StartUps and SMEs Companies

PARAGON-HF: Novartis Hangs Onto Hope For Entresto In HFpEF

Despite Phase III miss, Novartis is hopeful that the totality of the evidence will secure it at least a limited label expansion to a sizable but harder to treat portion of the heart failure market than Entresto already serves.

Cardiovascular Clinical Trials

Interview: AstraZeneca’s Pangalos on Landmark DAPA-HF Results

AstraZeneca’s head of R&D spoke to Scrip about the outstanding results for dapagliflozin in heart failure regardless of diabetes status.

Cardiovascular Clinical Trials

Farxiga Data Change Heart Failure Treatment Outlook

DAPA-HF data on AstraZeneca’s SGLT-2 inhibitor dapagliflozin as a treatment for heart failure in both diabetics and non-diabetics won spontaneous applause at ESC.

Cardiovascular Clinical Trials

Top 10 Drugs: Biologic Blockbusters And The Biosimilar Threat

INFOGRAPHIC: maturing cancer and autoimmune biologics still top the league for global revenues, but biosimilars are snapping at their heels.

 

Biologics Commercial
See All
Advertisement
UsernamePublicRestriction

Register